This product is the generic equivalent to Temodar® (temozolomide),
indicated for the treatment of adult patients with newly diagnosed
glioblastoma multiforme concomitantly with radiotherapy and then as
maintenance treatment and refractory anaplastic astrocytoma patients who
have experienced disease progression on a drug regimen containing
nitrosourea and procarbazine. Temodar® had annual sales of approximately
$423 million in the United States, according to IMS data as of December
31, 2012. The launch of this product provides a quality alternative,
making cancer therapy more cost effective for patients who suffer from
this devastating cancer.
Perrigo’s Chairman, President and CEO Joseph C. Papa stated, “This
first-to-file launch with our partner Teva is another example of our
focus to manufacture complex API’s. We are pleased to offer this
important product to patients in the United States.”
“We are pleased to partner with Perrigo to offer patients a
high-quality, less expensive alternative of this important medicine.
This launch demonstrates Teva’s commitment to continue to pursue
first-to-market opportunities and enhance the value of our portfolio by
concentrating on high-margin, low competition markets,” stated Allan
Oberman, President and CEO of Teva Americas Generics.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) is a leading global
pharmaceutical company, committed to increasing access to high-quality
healthcare by developing, producing and marketing affordable generic
drugs as well as innovative and specialty pharmaceuticals and active
pharmaceutical ingredients. Headquartered in Israel, Teva is the world's
leading generic drug maker, with a global product portfolio of more than
1,000 molecules and a direct presence in about 60 countries. Teva's
branded businesses focus on CNS, oncology, pain, respiratory and women's
health therapeutic areas as well as biologics. Teva currently employs
approximately 46,000 people around the world and reached $20.3 billion
in net revenues in 2012.
About Perrigo
From its beginnings as a packager of generic home remedies in 1887,
Allegan, Michigan-based Perrigo Company has grown to become a leading
global provider of quality, affordable healthcare products. Perrigo
develops, manufactures and distributes over-the-counter (OTC) and
generic prescription (Rx) pharmaceuticals, infant formulas, nutritional
products, animal health, dietary supplements and active pharmaceutical
ingredients (API). The Company is the world’s largest manufacturer of
OTC pharmaceutical products for the store brand market. The Company’s
primary markets and locations of logistics operations have evolved over
the years to include the United States, Israel, Mexico, the United
Kingdom, India, China and Australia. Visit Perrigo on the Internet (http://www.perrigo.com).
Teva's Safe Harbor Statement under the U. S. Private Securities
Litigation Reform Act of 1995:
This release contains forward-looking statements, which express the
current beliefs and expectations of management. Such statements are
based on management’s current beliefs and expectations and involve a
number of known and unknown risks and uncertainties that could cause our
future results, performance or achievements to differ significantly from
the results, performance or achievements expressed or implied by such
forward-looking statements. Important factors that could cause or
contribute to such differences include risks relating to: our ability to
develop and commercialize additional pharmaceutical products, including
our ability to develop, manufacture, market and sell biopharmaceutical
products, competition for our innovative products, especially Copaxone®
(including competition from innovative orally-administered alternatives,
as well as from potential purported generic equivalents), competition
for our generic products (including from other pharmaceutical companies
and as a result of increased governmental pricing pressures),
competition for our specialty pharmaceutical businesses, our ability to
achieve expected results through our specialty, including innovative,
R&D efforts, the effectiveness of our patents and other protections for
innovative products, decreasing opportunities to obtain U.S. market
exclusivity for significant new generic products, our ability to
identify, consummate and successfully integrate acquisitions, the
effects of increased leverage as a result of recent acquisitions, the
extent to which any manufacturing or quality control problems damage our
reputation for high quality production and require costly remediation,
our potential exposure to product liability claims to the extent not
covered by insurance, increased government scrutiny in both the U.S. and
Europe of our agreements with brand companies, potential liability for
sales of generic products prior to a final resolution of outstanding
patent litigation. our exposure to currency fluctuations and
restrictions as well as credit risks, the effects of reforms in
healthcare regulation and pharmaceutical pricing and reimbursement, any
failures to comply with complex Medicare and Medicaid reporting and
payment obligations, governmental investigations into sales and
marketing practices (particularly for our specialty pharmaceutical
products), uncertainties surrounding the legislative and regulatory
pathways for the registration and approval of biotechnology-based
products, adverse effects of political or economical instability,
corruption, major hostilities or acts of terrorism on our significant
worldwide operations, interruptions in our supply chain or problems with
our information technology systems that adversely affect our complex
manufacturing processes, any failure to retain key personnel or to
attract additional executive and managerial talent, the impact of
continuing consolidation of our distributors and customers, variations
in patent laws that may adversely affect our ability to manufacture our
products in the most efficient manner, potentially significant
impairments of intangible assets and goodwill, potential increases in
tax liabilities, the termination or expiration of governmental programs
or tax benefits, environmental risks and other factors that are
discussed in our Annual Report on Form 20-F for the year ended December
31, 2012 and in our other filings with the U.S. Securities and Exchange
Commission. Forward-looking statements speak only as of the date on
which they are made and the Company undertakes no obligation to update
or revise any forward-looking statement, whether as a result of new
information, future events or otherwise.
Perrigo’s Safe Harbor Statement: Certain statements in this press
release are forward-looking statements within the meaning of Section 21E
of the Securities Exchange Act of 1934, as amended, and are subject to
the safe harbor created thereby. These statements relate to future
events or the Company’s future financial performance and involve known
and unknown risks, uncertainties and other factors that may cause the
actual results, levels of activity, performance or achievements of the
Company or its industry to be materially different from those expressed
or implied by any forward-looking statements. In some cases,
forward-looking statements can be identified by terminology such as
“may,” “will,” “could,” “would,” “should,” “expect,” “plan,”
“anticipate,” “intend,” “believe,” “estimate,” “predict,” “potential” or
other comparable terminology. The Company has based these
forward-looking statements on its current expectations, assumptions,
estimates and projections. While the Company believes these
expectations, assumptions, estimates and projections are reasonable,
such forward-looking statements are only predictions and involve known
and unknown risks and uncertainties, many of which are beyond the
Company’s control. These and other important factors, including those
discussed under “Risk Factors” in the Company’s Form 10-K for the year
ended June 30, 2012, as well as the Company’s subsequent filings with
the Securities and Exchange Commission, may cause actual results,
performance or achievements to differ materially from those expressed or
implied by these forward-looking statements. The forward-looking
statements in this press release are made only as of the date hereof,
and unless otherwise required by applicable securities laws, the Company
disclaims any intention or obligation to update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise.
Source: Teva Pharmaceutical Industries Ltd. and Perrigo Company
Teva
IR:
Kevin C. Mannix, 215-591-8912
United
States
or
Ran Meir, 215-591-3033
United States
or
Tomer
Amitai, 972 (3) 926-7656
Israel
or
PR:
Iris
Beck Codner, 972 (3) 926-7246
Israel
or
Denise
Bradley, 215-591-8974
United States
or
Perrigo
IR:
Arthur
J. Shannon, 269-686-1709
ajshannon@perrigo.com
or
Bradley
Joseph, 269-686-3373
bradley.joseph@perrigo.com